Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F15%3A43910373" target="_blank" >RIV/00216208:11120/15:43910373 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/15:#0000487

Výsledek na webu

<a href="http://dx.doi.org/10.1186/s13054-015-1112-5" target="_blank" >http://dx.doi.org/10.1186/s13054-015-1112-5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s13054-015-1112-5" target="_blank" >10.1186/s13054-015-1112-5</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports

Popis výsledku v původním jazyce

INTRODUCTION: Propofol infusion syndrome (PRIS) is a rare, but potentially lethal adverse effect of a commonly used drug. We aimed to review and correlate experimental and clinical data about this syndrome. METHODS: We searched for all case reports published between 1990 and 2014 and for all experimental studies on PRIS pathophysiology. We analysed the relationship between signs of PRIS and the rate and duration of propofol infusion causing PRIS. By multivariate logistic regression we looked at the riskfactors for mortality. RESULTS: Knowledge about PRIS keeps evolving. Compared to earlier case reports in the literature, recently published cases describe older patients developing PRIS at lower doses of propofol, in whom arrhythmia, hypertriglyceridaemia and fever are less frequently seen, with survival more likely. We found that propofol infusion rate and duration, the presence of traumatic brain injury and fever are factors independently associated with mortality in reported cases of

Název v anglickém jazyce

Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports

Popis výsledku anglicky

INTRODUCTION: Propofol infusion syndrome (PRIS) is a rare, but potentially lethal adverse effect of a commonly used drug. We aimed to review and correlate experimental and clinical data about this syndrome. METHODS: We searched for all case reports published between 1990 and 2014 and for all experimental studies on PRIS pathophysiology. We analysed the relationship between signs of PRIS and the rate and duration of propofol infusion causing PRIS. By multivariate logistic regression we looked at the riskfactors for mortality. RESULTS: Knowledge about PRIS keeps evolving. Compared to earlier case reports in the literature, recently published cases describe older patients developing PRIS at lower doses of propofol, in whom arrhythmia, hypertriglyceridaemia and fever are less frequently seen, with survival more likely. We found that propofol infusion rate and duration, the presence of traumatic brain injury and fever are factors independently associated with mortality in reported cases of

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Critical Care

ISSN

1466-609X

e-ISSN

—

Svazek periodika

19

Číslo periodika v rámci svazku

Article ID 398

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

1-9

Kód UT WoS článku

000364556700001

EID výsledku v databázi Scopus

—